2017 Genitourinary Cancers Symposium

2017 Genitourinary Cancers Symposium

Adding Cisplatin to Standard Regimen Leads to Unprecedented Response Rate in Patients with Stage IV Pancreatic Cancer

The addition of cisplatin to standard therapy with gemcitabine and nab-paclitaxel was associated with a median overall survival that “has not been seen in stage IV pancreatic cancer,” according to [ Read More ]

2017 Genitourinary Cancers Symposium

Evidence Supports Active Surveillance for Small Renal Masses

Active surveillance is gaining ground as a strategy for managing small renal masses. According to intermediate follow-up of the prospective Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry, [ Read More ]

2017 Genitourinary Cancers Symposium

Atezolizumab/Bevacizumab Combo Looks Promising in Metastatic Kidney Cancer

Atezolizumab plus bevacizumab showed encouraging responses as a first-line approach to treatment of metastatic renal cell carcinoma (mRCC) in a phase 2 trial. Although the trial failed to meet its [ Read More ]

2017 Genitourinary Cancers Symposium

Patients’ Expectations of Treatment off Target

Despite consultations with oncologists about the goal of treatment, more than one-third of men with incurable prostate cancer believed that a cure was possible with the treatments they were about [ Read More ]

2017 Genitourinary Cancers Symposium

Reduced-Dose Sorafenib with Uptitration in Hepatocellular Carcinoma Is Cost-Saving Without Compromising Outcome

Starting at a low dose of sorafenib and titrating up to the full dose of 800 mg, rather than starting at the full dose, does not adversely affect outcomes and [ Read More ]

2017 Genitourinary Cancers Symposium

Concurrent EGFR and BRAF Inhibition Improves PFS in BRAF V600 Mutation–Positive Colorectal Cancer

Adding vemurafenib to cetuximab and irinotecan prolonged progression-free survival (PFS) and improved the disease control rate in patients with BRAF V600E mutation–positive colorectal cancer (CRC). The median PFS was extended [ Read More ]

2017 Genitourinary Cancers Symposium

Cabozantinib Active in Advanced Neuroendocrine Tumors

The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib demonstrated encouraging activity in patients with advanced neuroendocrine tumors (NETs), including patients previously treated with sunitinib or everolimus, a preliminary clinical study showed. [ Read More ]